This is in line with the previous findings in colon cancer (16), prostate cancer (17), non-small cell lung cancer (20), and melanoma (19), suggesting that IFN-γ treatment could globally enhance metastasis of cancers. This evidence concerns the gene IFNG and prostate cancer.